Abbott Laboratories: Analyst Ratings and Growth Prospects in MedTech and Non-MedTech
Abbott Laboratories: Analyst Ratings
Abbott Laboratories has captured the attention of analysts amid promising forecasts for both MedTech and non-MedTech segments. Recent insights indicate that Nutrition and Diagnostics revenues are set to experience easing over the next few years. This trajectory suggests a robust outlook with revenue growth predicted to be accompanied by margin expansion of 30 to 50 basis points annually through fiscal 2026.
Growth Drivers in MedTech
- Strength in cardiovascular devices.
- Innovations in diabetes care technologies.
Non-MedTech Insights
On the non-MedTech front, slowing comps could positively affect overall financial performance, allowing for reinvestment back into core business segments.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.